News: $ALRN Aileron Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update
Company continues to develop ALRN-6924 as novel chemoprotective medicine to protect patients from chemotherapy-induced toxicities and side effects -- Positive interim dose optimization data from proof-of-concept Phase 1b study, reported in second quarter 2020 Additional second quarter ...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.